BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Up 28.7% in November

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 688,400 shares, an increase of 28.7% from the November 15th total of 534,800 shares. Based on an average daily volume of 5,250,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.1% of the shares of the company are short sold.

BriaCell Therapeutics Price Performance

Shares of NASDAQ:BCTX remained flat at $0.66 during trading on Friday. The stock had a trading volume of 2,234,086 shares, compared to its average volume of 1,642,969. The stock has a market capitalization of $23.88 million, a P/E ratio of -0.56 and a beta of 1.46. BriaCell Therapeutics has a one year low of $0.46 and a one year high of $5.97. The company has a fifty day moving average price of $0.84 and a two-hundred day moving average price of $0.88.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings results on Monday, October 28th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.45. As a group, analysts forecast that BriaCell Therapeutics will post -1.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of BriaCell Therapeutics in a research report on Thursday.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. 15.42% of the stock is currently owned by institutional investors and hedge funds.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.